Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2018 7:00am EDT

XOMA to Present at the UBS Global Healthcare Conference

May 15, 2018 7:00am EDT

XOMA Reports First Quarter 2018 Financial Results

May 09, 2018 4:05pm EDT

XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model

May 08, 2018 7:00am EDT

XOMA to Present at the H.C. Wainwright Global Life Sciences Conference

Apr 03, 2018 7:00am EDT

XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Mar 07, 2018 4:05pm EST

XOMA to Present at the Cowen and Company 38th Annual Health Care Conference

Mar 05, 2018 7:00am EST

XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel

Jan 08, 2018 7:00am EST

XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.

Dec 07, 2017 8:35am EST

XOMA Reports Third Quarter 2017 Financial Results

Nov 06, 2017 4:05pm EST
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...43
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2023 XOMA Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2023 XOMA • Powered by GeneratePress
    Scroll back to top